What Makes Taiwanese Beauty Brand O’right Worthy of a Golden Ticket into the Nordics?
As the novel coronavirus spreads across the world, Taiwanese green beauty brand O’right continues to make significant strides in sustainability. This year, O’right made headlines with the opening of its store in Isetan Shinjuku, a leading department store in Japan. Now, the pioneering brand has made its way into Lyko, a Sweden-based beauty and hair care chain that has quickly become the Nordic region’s leading player in the segment. Recently, the green innovator celebrates the Good Design Gold Award (Japan’s Good Design Award is one of the top 4 design awards in the world) honor for its latest innovation – the world’s greenest toothpaste – to offer new green lifestyle solutions worldwide. O’right continues its commitment to doing what’s best for people, the society and earth and calls on businesses and people to follow suit. What started as a small, unknown name in Taiwan has now evolved into a zero carbon beauty brand that is taking the beauty sector by storm.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005486/en/
Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. (Photo: Business Wire)
A visionary brand that’s here to stay
O’right and the Swedish beauty retailer Lyko first crossed paths at Cosmoprof Bologna. Founded in the world’s most sustainable country, Lyko partners with brands and stocks products that align with its own values and meets its high standards. O’right has been leading the way to sustainability for years, from its innovative 8 Free standard for creating non-toxic, clean and multi-award-winning range of green products to recently receiving the USDA Certified Biobased Product Label. This year, the company aims to achieve zero carbon (carbon neutrality) for 77 of its products. O’right’s commitment to sustainability is shown not only in its values, but also from product formulations to packaging. The trailblazer demonstrates a positive social and environmental impact and powerful visionary narratives that justify its worth and inspire the Swedish-based chain to wholeheartedly invest in. It’s safe to say that the cosmetic world is excited to watch as the partnership between two companies that share the same values from the East and the West blossoms into something incredible.
Green without borders
Lyko boasts Sweden’s largest e-commerce site with an average monthly traffic count of 4 million visits, along with 37 physical stores in Sweden and Norway. Lyko joins forces with O’right, opening the door for the Taiwanese brand to make its green values and products seen in the Nordic region. O’right green products even made it into the e-commerce platform’s top sellers list. As a green zero carbon brand, O’right believes that the key to making a greater influence in every part of the world is to inspire green living and consumption. When it comes to sustainability, distance and national borders don’t matter.
Does O’right, a small Taiwanese company from the small land of Taiwan, have what it takes to conquer the eco beauty sector of the Nordic region? O’right is determined to show its green value and wow consumers with its holistic green lifestyle solutions and innovative trends.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005486/en/
Contact information
Lorella Chan
Public Relations Specialist
Phone: +886 (3) - 4116789
Email: Lorella_Chan@oright.com.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Regnology Signs an Agreement to Acquire Moody’s Regulatory Reporting & ALM Solutions18.12.2025 11:00:00 EET | Press release
Regnology, a leading provider in regulatory, risk, tax, and finance reporting, as well as supervisory technology, today announced it has signed an exclusive agreement for the acquisition of Moody’s Regulatory Reporting & ALM Solutions business, inclusive of solutions for Basel III compliance, IFRS9 impairment accounting, large bank asset-liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting across more than 50 jurisdictions. By integrating Moody’s regulatory capital and liquidity capabilities with Regnology’s regulatory, risk, and finance offerings, the firm is creating a unified, scalable platform designed to meet the full spectrum of financial regulatory compliance and risk requirements. This combined strength positions Regnology as the partner of choice for financial institutions seeking future-ready solutions. At the core of this strategy is Regnology Risk Hub (RRiskHub), an integrated solution designed to deliver a single
Reply Recognized as a Microsoft Azure Expert Managed Services Provider for the Sixth Consecutive Year18.12.2025 11:00:00 EET | Press release
Reply [EXM, STAR: REY] announced today it has been recognized once again as a Microsoft Azure Expert Managed Services Provider (MSP). The renewal reaffirms Reply’s proven expertise and consistent track record in delivering high-quality cloud solutions and services on the Microsoft Azure platform, powered by the deep technical expertise of its specialized companies – Cluster Reply, Solidsoft Reply and Valorem Reply. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218596617/en/ This recognition reflects the ongoing collaboration between Reply - through its companies Cluster Reply, Solidsoft Reply, and Valorem Reply - and Microsoft, supporting shared efforts to deliver value-driven services to enterprise customers. The Azure Expert MSP program is designed by Microsoft to identify and validate partners with proven capabilities in delivering end-to-end Azure services at scale. To qualify, partners must meet a strict set of requ
Takeda’s Zasocitinib Landmark Phase 3 Plaque Psoriasis Data Show Promise to Deliver Clear Skin in a Once-Daily Pill, Catalyzing a New Era of Treatment18.12.2025 10:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced positive topline results for the two pivotal Phase 3randomized, multicenter, double-blind, placebo- and active comparator-controlled studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO). The studies demonstrated superiority of zasocitinib compared to placebo for the co-primary endpoints, static Physician Global Assessment (sPGA) 0/1 and Psoriasis Area and Severity Index (PASI) 75, at week 16, with a significantly greater PASI 75 response rate seen as early as week 4 and continuing to increase through week 24. The studies also met all 44 ranked secondary endpoints, including PASI 90, PASI 100 and sPGA 0 against placebo and apremilast, showing the potential of a convenient once-daily pill to deliver complete skin clearance for patients with PsO. “People living with psoriasis continue to seek safe, effective and fast-acting oral therap
DATROWAY ® Type II Variation Application Validated in the EU as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who are Not Candidates for Immunotherapy18.12.2025 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for DATROWAY® (datopotamab deruxtecan) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. DATROWAY is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/Nasdaq: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use. The application is based on data from the TROPION-Breast02 phase 3 trial presented in a late-breaking proffered paper session at the 2025 European Society for Medical Oncology (#ESMO25) Congress. In the trial, DATROWAY demonstrated statistically significant and clinical
Celltrion receives positive CHMP Opinion for SteQeyma™ (ustekinumab biosimilar) autoinjector18.12.2025 04:41:00 EET | Press release
Celltrion, Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion of autoinjector of SteQeyma™, a biosimilar to Stelara® (ustekinumab), for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and Crohn’s disease (CD). The positive CHMP opinion is for SteQeyma autoinjector in 45mg/0.5mL and 90mg/1mL, expanding the currently approved SteQeyma™ presentation, which includes 45mg/0.5mL, 90mg/1mL in a pre-filled syringe and 45mg/0.5mL in a vial for subcutaneous injection, as well as 130mg/26mL concentrate for solution for intravenous infusion. “The new SteQeyma™ autoinjector brings together convenience and practical usability to meet the everyday challenges faced by patients living with chronic inflammatory diseases. The full range of our SteQeyma™ dosage forms and strengths, with the autoinjector now added, provides patients and healthcare professionals with more individualized treatm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
